Amino Collective
Kernal Bio seeks motivated mRNA-LNP Process Development Scientists to advance its therapeutic platform, focusing on developing and manufacturing mRNA-LNP therapeutics, and conducting analytical and preclinical testing. The role involves process development, process scale-up, analytical characterization, and supporting in vivo studies.
Amino Collective is an early-stage venture capital firm with a primary investment focus in health and biotech. The firm backs, connects, and supports entrepreneurs and scientists to bring life-changing ideas to life. It targets ventures with a European focus and ambition to scale globally.
Kernal Bio Joins Lilly Gateway Labs to Accelerate In Vivo Cell Therapies
Oct 3, 2025
Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease
Oct 7, 2025
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
Jul 7, 2022
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amino Collective.
27% below the average for this role
Kernal Biologics Enters Development Phase Reaching Critical
Jul 22, 2021